Inotrope; Phosphodiesterase-3 Enzyme Inhibitor

CCP: Acute decompensated heart failure

CCP: Inotropic support

• Hypersensitivity
• Avoid use in patients with severe obstructive aortic or pulmonic valvular disease

Cautions

• Arrhythmias
• Hypotension
• Renal dysfunction

Onset: 5-15 minutes

Half-life: 2.3 hours

Cardiovascular:

• Ventricular arrhythmia (ventricular ectopy, non-sustained ventricular tachycardia, ventricular tachycardia, ventricular fibrillation, atrial fibrillation, torsades de pointes
• Supraventricular cardiac arrhythmia, hypotension, angina pectoris, chest pain, myocardial infarction, thrombocytopenia,

Central nervous system

• Headache

Inflammatory

• Anaphylaxis

Dermatology

• Skin rash, injection site reaction

MSK

• Tremor

Respiratory

• Bronchospasm

Hepatic

• Hepatic insufficiency

• Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use.
• Immediate treatment of potential cardiac events, including life-threatening ventricular arrhythmias, must be available.
• Safe and effective use beyond 48 hours (prolonged use) has not been demonstrated.
• It is not known if milrinone is present in breast milk.

• Anagrelide
• Riociguat